These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
476 related articles for article (PubMed ID: 34071917)
21. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis. Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831 [TBL] [Abstract][Full Text] [Related]
22. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures. Ringheim GE; Wampole M; Oberoi K Front Immunol; 2021; 12():662223. PubMed ID: 34803999 [TBL] [Abstract][Full Text] [Related]
23. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity. Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810 [TBL] [Abstract][Full Text] [Related]
24. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018). Feng Y; Duan W; Cu X; Liang C; Xin M Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232 [TBL] [Abstract][Full Text] [Related]
25. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold. Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933 [TBL] [Abstract][Full Text] [Related]
26. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase. Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415 [TBL] [Abstract][Full Text] [Related]
27. Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas. Song PR; Wan ZP; Huang GG; Song ZL; Zhang T; Tong LJ; Fang Y; Tang HT; Xue Y; Zhan ZS; Feng F; Li Y; Shi WH; Huang YQ; Chen Y; Duan WH; Ding J; Zhang A; Xie H Acta Pharmacol Sin; 2024 Oct; 45(10):2163-2173. PubMed ID: 38834683 [TBL] [Abstract][Full Text] [Related]
28. Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens. Hopkins BT; Bame E; Bell N; Bohnert T; Bowden-Verhoek JK; Bui M; Cancilla MT; Conlon P; Cullen P; Erlanson DA; Fan J; Fuchs-Knotts T; Hansen S; Heumann S; Jenkins TJ; Marcotte D; McDowell B; Mertsching E; Negrou E; Otipoby KL; Poreci U; Romanowski MJ; Scott D; Silvian L; Yang W; Zhong M Bioorg Med Chem; 2019 Jul; 27(13):2905-2913. PubMed ID: 31138459 [TBL] [Abstract][Full Text] [Related]
29. A Fast and Clean BTK Inhibitor. Gabizon R; London N J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033 [TBL] [Abstract][Full Text] [Related]
30. Bruton's tyrosine kinase: oncotarget in myeloma. Tai YT; Anderson KC Oncotarget; 2012 Sep; 3(9):913-4. PubMed ID: 22989914 [TBL] [Abstract][Full Text] [Related]
31. Bruton's tyrosine kinase: A promising target for treating systemic lupus erythematosus. Ding Q; Zhou Y; Feng Y; Sun L; Zhang T Int Immunopharmacol; 2024 Dec; 142(Pt A):113040. PubMed ID: 39216117 [TBL] [Abstract][Full Text] [Related]
32. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases. De Bondt M; Renders J; Struyf S; Hellings N Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213 [TBL] [Abstract][Full Text] [Related]
33. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development. Huang W; Wang S; Zhang Z; Zhang C; Zeng S; Liang M; Shen Z; Liu X Bioorg Chem; 2020 Dec; 105():104377. PubMed ID: 33091668 [TBL] [Abstract][Full Text] [Related]
34. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. Bam R; Ling W; Khan S; Pennisi A; Venkateshaiah SU; Li X; van Rhee F; Usmani S; Barlogie B; Shaughnessy J; Epstein J; Yaccoby S Am J Hematol; 2013 Jun; 88(6):463-71. PubMed ID: 23456977 [TBL] [Abstract][Full Text] [Related]
35. Inhibiting Bruton's Tyrosine Kinase to Counteract Chemoresistance and Stem Cell-Like Properties in Osteosarcoma. Tsai HC; Lien MY; Wang SW; Fong YC; Tang CH Environ Toxicol; 2024 Nov; 39(11):4936-4945. PubMed ID: 38924303 [TBL] [Abstract][Full Text] [Related]
36. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK. Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717 [TBL] [Abstract][Full Text] [Related]
37. Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells. Bam R; Venkateshaiah SU; Khan S; Ling W; Randal SS; Li X; Zhang Q; van Rhee F; Barlogie B; Epstein J; Yaccoby S Blood Cancer J; 2014 Aug; 4(8):e234. PubMed ID: 25083818 [TBL] [Abstract][Full Text] [Related]
38. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors. Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612 [TBL] [Abstract][Full Text] [Related]